TABLE 2.
Common antibiogram phenotypes of MRSA isolates from 1996 through 2001
| Type | % of all MRSA isolates | Phenotype for antimicrobial agenta: |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| ERY | CLI | GEN | LEV-CIPb | OXA | RIF | SXT | TET | VAN | ||
| Major type | 64 | R | R | S | R | R | S | S | S | S |
| Type 2 | 8 | R | R | R | R | R | S | R | S | S |
| Type 3 | 7 | R | R | R | R | R | S | S | S | S |
| Type 4 | 5 | R | S | S | R | R | S | S | S | S |
| Type 5 | 3 | R | S | S | S | R | S | S | S | S |
| Type 6 | 3 | R | R | S | R | R | S | S | R | S |
| Type 7 | 2 | S | S | S | S | R | S | S | S | S |
a
All isolates were tested by using the Vitek system. ERY, erythromycin; CLI, clindamycin; GEN, gentamicin; LEV-CIP, levofloxacin-ciprofloxacin; OXA, oxacillin; RIF, rifampin; SXT, trimethoprim-sulfamethoxazole; TET, tetracycline; VAN, vancomycin. Phenotypes were determined by comparing the results of each antimicrobial susceptibility for the 6-year period. Isolates with intermediate results were considered resistant. Differences from the major phenotype are indicated in boldface.
b
Ciprofloxacin was tested for the years 1996 to 1998, and levofloxacin was tested for the years 1999 to 2001.